Top

Published in:

01-12-2019 | Lung Cancer | Review Article

Small cell carcinoma of the bladder: the characteristics of molecular alterations, treatment, and follow-up

Authors: Yanling Wang, Qijun Li, Jing Wang, Mengting Tong, Haibo Xing, Yanan Xue, Hongming Pan, Changxing Huang, Da Li

Published in: Medical Oncology | Issue 12/2019

Abstract

Small cell carcinoma of the bladder (SCCB) is a rare disease associated with high invasiveness and mortality. Histologically, SCCB is difficult to distinguish from small cell lung cancer (SCLC); however, it shares more similar molecular alterations with urothelial carcinoma (UC). As a result, now, the widely accepted theory about the cells of origin is that SCCB and UC probably have a common clone origin. Even the former probably comes from a preexisting UC. At present, given its rarity, early diagnoses, treatments, and follow-ups are not well established, which are vital to patients with SCCB. Inspirationally, in recent years, with the development of molecular diagnostic methods, molecular alterations of SCCB have been understood partially, which are propitious to excavate new potential therapeutic strategies and establish sound follow-ups. Therefore, the future will be light for patients with SCCB.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. https://doi.org/10.3322/caac.21442.CrossRefPubMed

Niu Q, Lu Y, Xu S, Shi Q, Guo B, Guo Z, et al. Clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: a population-based study. Cancer Manag Res. 2018;10:4479–89. https://doi.org/10.2147/CMAR.S175286.CrossRefPubMedPubMedCentral

Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur Urol. 2016;70(1):106–19. https://doi.org/10.1016/j.eururo.2016.02.028.CrossRefPubMed

Erdem GU, Ozdemir NY, Demirci NS, Sahin S, Bozkaya Y, Zengin N. Small cell carcinoma of the urinary bladder: changing trends in the current literature. Curr Med Res Opin. 2016;32(6):1013–21. https://doi.org/10.1185/03007995.2016.1155982.CrossRefPubMed

Schreiber D, Rineer J, Weiss J, Leaf A, Karanikolas N, Rotman M, et al. Characterization and outcomes of small cell carcinoma of the bladder using the surveillance, epidemiology, and end results database. Am J Clin Oncol Cancer. 2013;36(2):126–31. https://doi.org/10.1097/COC.0b013e3182438c71.CrossRef

Chang MT, Penson A, Desai NB, Socci ND, Shen R, Seshan VE, et al. Small-cell carcinomas of the bladder and lung are characterized by a convergent but distinct pathogenesis. Clin Cancer Res. 2018;24(8):1965–73. https://doi.org/10.1158/1078-0432.CCR-17-2655.CrossRefPubMed

Shen PY, Jing Y, Zhang RY, Cai MC, Ma P, Chen H, et al. Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics. Oncogene. 2018;37(22):3039–44. https://doi.org/10.1038/s41388-018-0192-5.CrossRefPubMed

Oser MG, Janne PA. Small-cell neuroendocrine tumors: cell state trumps the oncogenic driver. Clin Cancer Res. 2018;24(8):1775–6. https://doi.org/10.1158/1078-0432.CCR-17-3646.CrossRefPubMedPubMedCentral

Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540.e25–556.e25. https://doi.org/10.1016/j.cell.2017.09.007.CrossRef

10.

Peifer M, Fernandez-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012;44(10):1104–10. https://doi.org/10.1038/ng.2396.CrossRefPubMedPubMedCentral

11.

Augert A, Zhang Q, Bates B, Cui M, Wang X, Wildey G, et al. Small cell lung cancer exhibits frequent inactivating mutations in the histone methyltransferase KMT2D/MLL2: CALGB 151111 (alliance). J Thorac Oncol. 2017;12(4):704–13. https://doi.org/10.1016/j.jtho.2016.12.011.CrossRefPubMed

12.

Fischer M. Census and evaluation of p53 target genes. Oncogene. 2017;36(28):3943–56. https://doi.org/10.1038/onc.2016.502.CrossRefPubMedPubMedCentral

13.

Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012;26(12):1268–86. https://doi.org/10.1101/gad.190678.112.CrossRefPubMedPubMedCentral

14.

Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505(7484):495–501. https://doi.org/10.1038/nature12912.CrossRefPubMedPubMedCentral

15.

Berman-Booty LD, Knudsen KE. Models of neuroendocrine prostate cancer. Endocr Relat Cancer. 2015;22(1):R33–49. https://doi.org/10.1530/ERC-14-0393.CrossRefPubMed

16.

Di Agostino S, Fontemaggi G, Strano S, Blandino G, D’Orazi G. Targeting mutant p53 in cancer: the latest insights. J Exp Clin Cancer Res. 2019;38(1):290. https://doi.org/10.1186/s13046-019-1302-0.CrossRefPubMedPubMedCentral

17.

Mantovani F, Collavin L, Del Sal G. Mutant p53 as a guardian of the cancer cell. Cell Death Differ. 2019;26(2):199–212. https://doi.org/10.1038/s41418-018-0246-9.CrossRefPubMed

18.

Kim MP, Lozano G. Mutant p53 partners in crime. Cell Death Differ. 2018;25(1):161–8. https://doi.org/10.1038/cdd.2017.185.CrossRefPubMed

19.

Nag S, Zhang X, Srivenugopal KS, Wang MH, Wang W, Zhang R. Targeting MDM2-p53 interaction for cancer therapy: are we there yet? Curr Med Chem. 2014;21(5):553–74. https://doi.org/10.2174/09298673113206660325.CrossRefPubMedPubMedCentral

20.

Frezza AM, Assi T, Lo Vullo S, Ben-Ami E, Dufresne A, Yonemori K, et al. Systemic treatments in MDM2 positive intimal sarcoma: a multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. Cancer. 2019. https://doi.org/10.1002/cncr.32508.CrossRefPubMed

21.

Zhang Q, Zeng SX, Lu H. Targeting p53-MDM2-MDMX loop for cancer therapy. Subcell Biochem. 2014;85:281–319. https://doi.org/10.1007/978-94-017-9211-0_16.CrossRefPubMedPubMedCentral

22.

Yang L, Song T, Cheng Q, Chen L, Chen J. Mutant p53 sequestration of the MDM2 acidic domain inhibits E3 ligase activity. Mol Cell Biol. 2019. https://doi.org/10.1128/mcb.00375-18.CrossRefPubMedPubMedCentral

23.

Dyson NJ. RB1: a prototype tumor suppressor and an enigma. Genes Dev. 2016;30(13):1492–502. https://doi.org/10.1101/gad.282145.116.CrossRefPubMedPubMedCentral

24.

D’Arcangelo D, Tinaburri L, Dellambra E. The role of p16(INK4a) pathway in human epidermal stem cell self-renewal, aging and cancer. Int J Mol Sci. 2017. https://doi.org/10.3390/ijms18071591.CrossRefPubMedPubMedCentral

25.

Fu HC, Chuang IC, Yang YC, Chuang PC, Lin H, Ou YC, et al. Low P16(INK4A) expression associated with high expression of cancer stem cell markers predicts poor prognosis in cervical cancer after radiotherapy. Int J Mol Sci. 2018. https://doi.org/10.3390/ijms19092541.CrossRefPubMedPubMedCentral

26.

He SH, Sharpless NE. Senescence in health and disease. Cell. 2017;169(6):1000–11. https://doi.org/10.1016/j.cell.2017.05.015.CrossRefPubMedPubMedCentral

27.

Noe M, Hackeng WM, de Leng WWJ, Vergeer M, Vleggaar FP, Morsink FHM, et al. Well-differentiated pancreatic neuroendocrine tumor in a patient with familial atypical multiple mole melanoma syndrome (FAMMM). Am J Surg Pathol. 2019. https://doi.org/10.1097/PAS.0000000000001314.CrossRefPubMed

28.

George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Kong G, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524(7563):47–53. https://doi.org/10.1038/nature14664.CrossRefPubMedPubMedCentral

29.

Meder L, Konig K, Ozretic L, Schultheis AM, Ueckeroth F, Ade CP, et al. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. Int J Cancer. 2016;138(4):927–38. https://doi.org/10.1002/ijc.29835.CrossRefPubMed

30.

Al-Ahmadie H, Iyer G, Hohl M, Asthana S, Inagaki A, Schultz N, et al. Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. Cancer Discov. 2014;4(9):1014–21. https://doi.org/10.1158/2159-8290.CD-14-0380.CrossRefPubMedPubMedCentral

31.

Rickman DS, Beltran H, Demichelis F, Rubin MA. Biology and evolution of poorly differentiated neuroendocrine tumors. Nat Med. 2017;23(6):1–10. https://doi.org/10.1038/nm.4341.CrossRefPubMed

32.

Cheng L, Jones TD, McCarthy RP, Eble JN, Wang MS, MacLennan GT, et al. Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am J Pathol. 2005;166(5):1533–9. https://doi.org/10.1016/S0002-9440(10)62369-3.CrossRefPubMedPubMedCentral

33.

Pan CX, Zhang H, Lara PN Jr, Cheng L. Small-cell carcinoma of the urinary bladder: diagnosis and management. Expert Rev Anticancer Ther. 2006;6(12):1707–13. https://doi.org/10.1586/14737140.6.12.1707.CrossRefPubMed

34.

Abat D, Demirhan O, Inandiklioglu N, Tunc E, Erdogan S, Tastemir D, et al. Genetic alterations of chromosomes, p53 and p16 genes in low- and high-grade bladder cancer. Oncol Lett. 2014;8(1):25–32. https://doi.org/10.3892/ol.2014.2108.CrossRefPubMedPubMedCentral

35.

Worst TS, Weis CA, Stohr R, Bertz S, Eckstein M, Otto W, et al. CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making. Sci Rep. 2018. https://doi.org/10.1038/s41598-018-32569-x.CrossRefPubMedPubMedCentral

36.

Kouba EJ, Cheng L. Understanding the genetic landscape of small cell carcinoma of the urinary bladder and implications for diagnosis, prognosis, and treatment: a review. JAMA Oncol. 2017;3(11):1570–8. https://doi.org/10.1001/jamaoncol.2016.7013.CrossRefPubMed

37.

Gupta A, Shah K, Oza MJ, Behl T. Reactivation of p53 gene by MDM2 inhibitors: a novel therapy for cancer treatment. Biomed Pharmacother. 2019;109:484–92. https://doi.org/10.1016/j.biopha.2018.10.155.CrossRefPubMed

38.

Khurana A, Shafer DA. MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388). Oncotargets Ther. 2019;12:2903–10. https://doi.org/10.2147/Ott.S172315.CrossRef

39.

Oliner JD, Saiki AY, Caenepeel S. The role of MDM2 amplification and overexpression in tumorigenesis. Cold Spring Harb Perspect Med. 2016. https://doi.org/10.1101/cshperspect.a026336.CrossRefPubMedPubMedCentral

40.

Weisberg E, Halilovic E, Cooke VG, Nonami A, Ren T, Sanda T, et al. Inhibition of wild-type p53-expressing AML by the novel small molecule HDM2 inhibitor CGM097. Mol Cancer Ther. 2015;14(10):2249–59. https://doi.org/10.1158/1535-7163.Mct-15-0429.CrossRefPubMedPubMedCentral

41.

Giedl J, Rogler A, Wild A, Riener MO, Filbeck T, Burger M, et al. TERT core promotor mutations in early-onset bladder cancer. J Cancer. 2016;7(8):915–20. https://doi.org/10.7150/jca.15006.CrossRefPubMedPubMedCentral

42.

Avogbe PH, Manel A, Vian E, Durand G, Forey N, Voegele C, et al. Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer. EBioMedicine. 2019;44:431–8. https://doi.org/10.1016/j.ebiom.2019.05.004.CrossRefPubMedPubMedCentral

43.

Zheng XY, Jian ZG, Bezerra SM, Faraj SF, Munari E, Fallon JT, et al. High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins. J Hematol Oncol. 2014. https://doi.org/10.1186/s13045-014-0047-7.CrossRefPubMedPubMedCentral

44.

Rane JK, Simms MS, Maitland NJ. Re: Yves Allorya, Willemien Beukers, Ana Sagrera, et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 2014;65:360-6: telomerase expression and stem cells: urologic epithelial perspective. Eur Urol. 2014;65(6):E85–6. https://doi.org/10.1016/j.eururo.2014.02.030.CrossRefPubMed

45.

Kinde I, Munari E, Faraj SF, Hruban RH, Schoenberg M, Bivalacqua T, et al. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Can Res. 2013;73(24):7162–7. https://doi.org/10.1158/0008-5472.Can-13-2498.CrossRef

46.

Fujii T, Shimada K, Tatsumi Y, Hatakeyama K, Obayashi C, Fujimoto K, et al. microRNA-145 promotes differentiation in human urothelial carcinoma through down-regulation of syndecan-1. BMC Cancer. 2015;15:818. https://doi.org/10.1186/s12885-015-1846-0.CrossRefPubMedPubMedCentral

47.

Van Batavia J, Yamany T, Molotkov A, Dan H, Mansukhani M, Batourina E, et al. Bladder cancers arise from distinct urothelial sub-populations. Nat Cell Biol. 2014;16(10):982–91. https://doi.org/10.1038/ncb3038.CrossRefPubMed

48.

Micke P, Faldum A, Metz T, Beeh KM, Bittinger F, Hengstler JG, et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer: what limits limited disease? Lung Cancer. 2002;37(3):271–6.CrossRef

49.

Nicholson AG, Chansky K, Crowley J, Beyruti R, Kubota K, Turrisi A, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(3):300–11. https://doi.org/10.1016/j.jtho.2015.10.008.CrossRefPubMed

50.

Bryant CM, Dang LH, Stechmiller BK, Gilbert SM, Morris CG, Zlotecki RA. Treatment of small cell carcinoma of the bladder with chemotherapy and radiation after transurethral resection of a bladder tumor. Am J Clin Oncol. 2016;39(1):69–75. https://doi.org/10.1097/COC.0000000000000027.CrossRefPubMed

51.

Montie JE. Small cell carcinoma of the urinary bladder. A clinicopathologic analysis of 64 patients. J Urol. 2005;173(6):1920–1. https://doi.org/10.1097/01.ju.0000161245.95285.b2.CrossRefPubMed

52.

Siefker-Radtke AO, Dinney CP, Abrahams NA, Moran C, Shen Y, Pisters LL, et al. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M.D. Anderson cancer experience. J Urol. 2004;172(2):481–4.CrossRef

53.

Quek ML, Nichols PW, Yamzon J, Daneshmand S, Miranda G, Cai J, et al. Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern california experience. J Urol. 2005;174(1):93–6. https://doi.org/10.1097/01.ju.0000162085.20043.1f.CrossRefPubMed

54.

Walther PJ. Adjuvant/neo-adjuvant etoposide/cisplatin and cystectomy for management of invasive small cell carcinoma of the bladder. J Urol. 2002;167(4):285.

55.

Pasquier D, Barney B, Sundar S, Poortmans P, Villa S, Nasrallah H, et al. Small cell carcinoma of the urinary bladder: a retrospective, multicenter rare cancer network study of 107 patients. Int J Radiat Oncol Biol Phys. 2015;92(4):904–10. https://doi.org/10.1016/j.ijrobp.2015.03.019.CrossRefPubMed

56.

Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Qiao W, Thall PF, et al. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol. 2009;27(16):2592–7. https://doi.org/10.1200/Jco.2008.19.0256.CrossRefPubMedPubMedCentral

57.

Lynch SP, Shen Y, Kamat A, Grossman HB, Shah JB, Millikan RE, et al. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol. 2013;64(2):307–13. https://doi.org/10.1016/j.eururo.2012.04.020.CrossRefPubMed

58.

Bhatt VR, Loberiza FR Jr, Tandra P, Krishnamurthy J, Shrestha R, Wang J. Risk factors, therapy and survival outcomes of small cell and large cell neuroendocrine carcinoma of urinary bladder. Rare Tumors. 2014;6(1):5043. https://doi.org/10.4081/rt.2014.5043.CrossRefPubMedPubMedCentral

59.

Kaushik D, Frank I, Boorjian SA, Cheville JC, Eisenberg MS, Thapa P, et al. Long-term results of radical cystectomy and role of adjuvant chemotherapy for small cell carcinoma of the bladder. Int J Urol. 2015;22(6):549–54. https://doi.org/10.1111/iju.12729.CrossRefPubMed

60.

Lohrisch C, Murray N, Pickles T, Sullivan L. Small cell carcinoma of the bladder: long term outcome with integrated chemoradiation. Cancer. 1999;86(11):2346–52.CrossRef

61.

Meijer RP, Meinhardt W, van der Poel HG, van Rhijn BW, Kerst JM, Pos FJ, et al. Local control rate and prognosis after sequential chemoradiation for small cell carcinoma of the bladder. Int J Urol. 2013;20(8):778–84. https://doi.org/10.1111/iju.12038.CrossRefPubMed

62.

Bex A, Nieuwenhuijzen JA, Kerst M, Pos F, van Boven H, Meinhardt W, et al. Small cell carcinoma of bladder: a single-center prospective study of 25 cases treated in analogy to small cell lung cancer. Urology. 2005;65(2):295–9. https://doi.org/10.1016/j.urology.2004.09.049.CrossRefPubMed

63.

Bex A, de Vries R, Pos F, Kerst M, Horenblas S. Long-term survival after sequential chemoradiation for limited disease small cell carcinoma of the bladder. World J Urol. 2009;27(1):101–6. https://doi.org/10.1007/s00345-008-0304-x.CrossRefPubMed

64.

Mattes MD, Kan CC, Dalbagni G, Zelefsky MJ, Kollmeier MA. External beam radiation therapy for small cell carcinoma of the urinary bladder. Pract Radiat Oncol. 2015;5(1):e17–22. https://doi.org/10.1016/j.prro.2014.03.013.CrossRefPubMed

65.

Akamatsu H, Nakamura K, Ebara T, Inaba K, Itasaka S, Jingu K, et al. Organ-preserving approach via radiotherapy for small cell carcinoma of the bladder: an analysis based on the Japanese Radiation Oncology Study Group (JROSG) survey. J Radiat Res. 2019. https://doi.org/10.1093/jrr/rrz018.CrossRefPubMedPubMedCentral

66.

Germino E, Fischer-Valuck BW, Rudra S, Rao YJ, Contreras J, Abraham C, et al. Radiation therapy as definitive local treatment in patients with limited-stage small cell carcinoma of the bladder: does total dose matter? Bladder Cancer. 2018;4(3):311–7. https://doi.org/10.3233/BLC-180165.CrossRefPubMedPubMedCentral

67.

van de Kamp M, Meijer R, Pos F, Kerst M, van Werkhoven E, van Rhijn B, et al. Intravesical recurrence after bladder sparing treatment of small cell carcinoma of the bladder: characteristics, treatment, and outcome. Urol Oncol. 2018;36(6):307.e1–8. https://doi.org/10.1016/j.urolonc.2018.02.015.CrossRef

68.

Hsu FS, Su CH, Huang KH. A comprehensive review of US FDA-approved immune checkpoint inhibitors in urothelial carcinoma. J Immunol Res. 2017;2017:6940546. https://doi.org/10.1155/2017/6940546.CrossRefPubMedPubMedCentral

69.

Schultheis AM, Scheel AH, Ozretic L, George J, Thomas RK, Hagemann T, et al. PD-L1 expression in small cell neuroendocrine carcinomas. Eur J Cancer. 2015;51(3):421–6. https://doi.org/10.1016/j.ejca.2014.12.006.CrossRefPubMed

70.

Koshkin VS, Garcia JA, Reynolds J, Elson P, Magi-Galluzzi C, McKenney JK, et al. Transcriptomic and protein analysis of small-cell bladder cancer (SCBC) identifies prognostic biomarkers and DLL3 as a relevant therapeutic target. Clin Cancer Res. 2019;25(1):210–21. https://doi.org/10.1158/1078-0432.Ccr-18-1278.CrossRefPubMed

71.

Mandelkow T, Blessin NC, Lueerss E, Pott L, Simon R, Li WC, et al. Immune exclusion is frequent in small-cell carcinoma of the bladder. Dis Markers. 2019. https://doi.org/10.1155/2019/2532518.CrossRefPubMedPubMedCentral

72.

Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321–30. https://doi.org/10.1038/nature21349.CrossRefPubMed

Title: Small cell carcinoma of the bladder: the characteristics of molecular alterations, treatment, and follow-up
Authors: Yanling Wang
Qijun Li
Jing Wang
Mengting Tong
Haibo Xing
Yanan Xue
Hongming Pan
Changxing Huang
Da Li
Publication date: 01-12-2019
Publisher: Springer US
Keywords: Lung Cancer
Lung Cancer
Cystectomy
SCLC
Bladder Carcinoma
Bladder Carcinoma
Lung Cancer
SCLC
Urothelial Cancer
Urothelial Cancer
Cytostatic Therapy
Published in: Medical Oncology / Issue 12/2019
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-019-1321-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2019

Can synthetic lethality approach be used with DNA repair genes for primary and secondary MDS?

Correction to: Outcomes of hypercalcemia of malignancy in patients with solid cancer: a national inpatient analysis

Caffeine enhances the anti-tumor effect of 5-fluorouracil via increasing the production of reactive oxygen species in hepatocellular carcinoma

A novel role mediated by adenoviral E1A in suppressing cancer through modulating decorin

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials